Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young Ho | - |
dc.contributor.author | Bae, Sang-Cheol | - |
dc.date.accessioned | 2021-09-02T14:44:44Z | - |
dc.date.available | 2021-09-02T14:44:44Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-03 | - |
dc.identifier.issn | 1756-1841 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/77246 | - |
dc.description.abstract | AimThis study aimed to evaluate the relationship between circulating adiponectin and visfatin levels and rheumatoid arthritis (RA) and to establish a correlation between serum adipokine levels and RA activity. MethodsWe conducted meta-analyses on serum/plasma adiponectin or visfatin levels in patients with RA and controls and correlation coefficients between circulating adiponectin and visfatin levels and Disease Activity Score of 28 joints (DAS28) in RA patients. ResultsEleven studies comprising 813 RA patients and 684 controls were included in this meta-analysis. The meta-analysis revealed that adiponectin levels were significantly higher in the RA group than in the control group (standardized mean difference [SMD] = 1.529, 95% confidence interval [CI] = 0.354-2.704, P = 0.011). Circulating adiponectin level was not associated with RA activity based on DAS28 and C-reactive protein (CRP) levels. Visfatin levels were significantly higher in the RA group than in the control group (SMD = 2.575, 95% CI: = 0.963-4.189, P = 0.002). A trend of positive correlation among circulating visfatin levels and DAS28 and CRP levels was found (correlation coefficient = 0.416, 95% CI: = -0.917 to 0.795, P = 0.177; correlation coefficient = 0.366, 95% CI: = -0.074 to 0.687, P = 0.101, respectively). ConclusionsOur meta-analysis demonstrated that circulating adiponectin levels were significantly higher in patients with RA than in controls. Circulating visfatin levels were significantly higher in patients with RA than in controls and a positive correlation between circulating visfatin level and RA activity is suggested. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | MOLECULAR-WEIGHT | - |
dc.subject | KAPPA-B | - |
dc.subject | RESISTIN | - |
dc.subject | LEPTIN | - |
dc.subject | BIAS | - |
dc.title | Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young Ho | - |
dc.identifier.doi | 10.1111/1756-185X.13038 | - |
dc.identifier.scopusid | 2-s2.0-85013329012 | - |
dc.identifier.wosid | 000426508200009 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, v.21, no.3, pp.664 - 672 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | - |
dc.citation.title | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | - |
dc.citation.volume | 21 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 664 | - |
dc.citation.endPage | 672 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | MOLECULAR-WEIGHT | - |
dc.subject.keywordPlus | KAPPA-B | - |
dc.subject.keywordPlus | RESISTIN | - |
dc.subject.keywordPlus | LEPTIN | - |
dc.subject.keywordPlus | BIAS | - |
dc.subject.keywordAuthor | adiponectin | - |
dc.subject.keywordAuthor | rheumatoid arthritis | - |
dc.subject.keywordAuthor | visfatin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.